ADC Sequencing and the "Sandwich" method

The dangers of cross-trial comparisons

Why it's hard to compare adverse events across trials Capitello-291: https://www.nejm.org/doi/full/10.1056/NEJMoa2214131 Capitello-281: https://pubmed.ncbi.nlm.nih.gov/41120017/

Thoughts on RASolute 302 (for 20 minutes)

RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

ADC Sequencing and the "Sandwich" method

What we do and do not understand about antibody drug conjugate sequencing. Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltext [https://www.jto.org/article/S1556-0864(26)00007-9/fulltext]Post mortem sacituzumab govitecan study:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/ [https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/]

Is HRR really a biomarker in prostate cancer?

Why HRR gene mutations are not the perfect biomarker. PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltext TALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract TRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

Interpreting prospective ctDNA trials

Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker